

Pharmacy & Therapeutics Committee News

September 2020

P & T Committee materials and references available upon request.

Kcentra Replaces FEIBA for Factor Xa Inhibitor Rescue

Kcentra and FEIBA are both prothrombin complex concentrates (PCC). FEIBA is an activated PCC (aPCC) due to the presence of activated Factor VII. There is otherwise very little difference in the procoagulant ability between the products containing Factors II, VII, IX and X. Kcentra will replace FEIBA as the formulary agent for the rescue of Factor Xa inhibitor induced intracranial hemorrhage or life threatening bleeding. National guidelines do not delineate one product over the other and conversion to Kcentra is a move to streamline our formulary, to align with the community and with Trinity. The same thought process and dose you would use for FEIBA is what you would use for Kcentra and the Kcentra order set has been revised to work through that process.

Restricted Medication List Policy Revisions

| | |
|--|---|
| Gemcitabine, Intravesical | Gemcitabine, intravesical is the treatment of choice. Mitomycin may be used for the following: gemcitabine failure, shortage or prior documented gemcitabine adverse event. |
| Mitomycin C, Intravesical | Gemcitabine, intravesical is the treatment of choice. Exceptions: gemcitabine failure, shortage or prior documented gemcitabine adverse event. |
| Prothrombin complex concentrate (Kcentra) | Approved uses: Intracranial hemorrhage due to warfarin or Factor Xa inhibitor Critical/Life threatening bleeding due to warfarin or Factor Xa inhibitor Major surgery required in < 3 hours (warfarin or Factor Xa inhibitor patient). |
| Zulresso (brexanolone) IV | Nonformulary, not stocked. |
| Buprenorphine transdermal (Butrans) | 1. If a patient is already on transdermal buprenorphine prior to admission, the ordered may be continued in the inpatient setting. No restrictions on the clinician who can order it. 2. No new starts in the hospital. |
| Isotretinoin (Accutane) PO | Nonformulary, not stocked. |
| Zostavax & Shingrix (zoster/shingles vaccine) | Shingrix: nonformulary for in-patients; formulary for out-patients. Zostavax is discontinued by the manufacturer and nonformulary. |
| Dornase/alteplase Intrapleural | Limited to patients who are not surgical candidates (ie too frail for thoracotomy incision). Re-evaluate after 2 doses. May repeat, but not to exceed 4 doses. Limit administration to clinical affiliates and MD only; this is standard for all other intrapleural drug administrations. |
| Formoterol/Arfomoterol Inhaled (Brovana, Foradil, Perforomist) | Foradil is no longer manufactured in the United States. Foradil and Brovana are nonformulary, not stocked. Orders for Brovana and Foradil will be automatically converted to Perforomist. See Therapeutic Substitution policy: Effective once the Brovana inventory is depleted. |
| Ranitidine (Zantac) | Ranitidine is no longer available due to nitrosamine contamination recalls. Famotidine (Pepcid) will be substituted. |
| Poractant (Curosurf) | Curosurf is the Formulary surfactant for Trinity and St. Joseph's Health. All surfactants, including nonformulary agents beractant (Suvanta) and calfactant (Infasurf) are restricted to neonates. |

Automatic Therapeutic Substitution Policy Revisions

| If Ordered | Interchange | Notes/Exceptions |
|--|--|---|
| Brovana (arformoterol) 15mcg/2ml neb INH q12h | Perforomist (formoterol) 20mcg neb sol INH q12h | Conversion from Brovana to Perforomist will only occur after the Brovana inventory is depleted. |
| Any H2 antagonist | Famotidine (Pepcid) | Ranitidine is on nationwide shortage due to nitrosamine contamination. |